OBJECTIVE： To systematically review the effectiveness and safety of liraglutide in the body mass loss of patients with overweight and obesity， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from Medline， EMBase， CJFD， Wanfang and VIP， randomized controlled trials （RCT） about liraglutide versus placebo in the treatment of overweight and obesity were collected. Meta-analysis was performed by using Rev Man 5.1.0 software after data extract. RESULTS： Totally 8 RCTs were enrolled， involving 3 560 patients. Results of Meta-analysis showed weight loss degree [MD＝－1.71， 95％Cl （－2.25，－1.17）， P＜0.001] and the percentage of proportion loss more than 5％ to total patients [RR＝2.20，95％CI（1.83， 2.63），P＜0.001] in liraglutide group were significnatly more than blank control group； while the incidences of nausea， vomiting， diarrhea， mild-to-moderate hypoglycemia and peripheral edema were significantly higher than control group. CONCLUSIONS： Liraglutide is effective for overweight and obesity patients. And there is mild adverse reactions but high incidence of gastrointestinal adverse reactions， which should be vigilant.